First Horizon Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

First Horizon Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$7.67K	Buy	+211	New	+$7.61K	﹤0.01%	1752
2022 Q3	–	Sell	-4	Closed	–	–	2417
2022 Q2	$0	Buy	+4	New	+$246	﹤0.01%	2510
2022 Q1	–	Sell	-4	Closed	–	–	2175
2021 Q4	$0	Buy	+4	New	+$325	﹤0.01%	2400
2020 Q3	–	Sell	-142	Closed	-$11K	–	1511
2020 Q2	$11K	Hold	142	–	–	﹤0.01%	984
2020 Q1	$6K	Buy	+142	New	+$7.37K	﹤0.01%	1081

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

First Horizon Advisors's RARE Position: Q2 2025 in Review

First Horizon Advisors opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2025: 211 shares worth $7.67K. The stake represents ﹤0.01% of the portfolio and ranks #1752 among its holdings. This is a return to the name: First Horizon Advisors previously reported a position in RARE as recently as Q2 2022.

First Horizon Advisors first reported a position in RARE in Q1 2020 and has held it in 5 quarters since. The position peaked at $11K in Q2 2020. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

First Horizon Advisors held 211 shares of Ultragenyx Pharmaceutical worth $7.67K as of Q2 2025.
Ultragenyx Pharmaceutical was a new First Horizon Advisors position in Q2 2025.
Ultragenyx Pharmaceutical made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1752 holding.
First Horizon Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and has held it in 5 quarters since.
First Horizon Advisors's Ultragenyx Pharmaceutical position peaked at $11K in Q2 2020.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.